PNC-27

PNC-27 is a synthetic chimeric peptide that joins a sequence derived from the p53 protein with penetratin, a membrane-penetrating peptide sequence. It has been studied as an experimental anti-cancer peptide in laboratory settings. Published work describes PNC-27 binding to HDM-2 in a structure resembling a p53 peptide. Research to date has been conducted in cell-culture, in vitro and ex vivo models rather than in human clinical trials.

Studies report that PNC-27 binds to HDM-2 located in the plasma membrane of cancer cells. This interaction has been associated with selective membrane-pore formation, leading to cancer cell lysis and necrosis. A 2024 study also described interactions with mitochondrial membranes that caused mitochondrial disruption. Earlier work reported that the peptide induces tumor cell lysis as the intact peptide. Because normal cells reportedly display less membrane HDM-2, this has been proposed as a basis for selectivity.

Laboratory studies have examined PNC-27 in leukemia cell lines, colon cancer cells and stem-like colonic progenitor cells, cervical cancer cells, and patient-derived epithelial ovarian cancer cells ex vivo. One study examined synergy between paclitaxel and PNC-27 in ovarian cancer models. Another conjugated PNC-27 to superparamagnetic iron oxide nanoparticles as a potential in vitro cancer detection agent. These findings are preclinical and have not been confirmed in human trials.

Human safety data are limited, and adverse events in people are not summarized in the cited studies. At the cellular level, researchers reported that PNC-27 induced necrosis in leukemia cells but not in normal hematopoietic cells, and killed cervical cancer cells but not normal cervical cells. These in vitro observations of selectivity do not establish safety in living organisms, and further research would be needed to characterize tolerability.

Research protocols have used 250–2,000 mcg per administration by the subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what protocols have used and are not recommendations. The published cell-culture studies cited here do not establish dosing in humans. Each CoreX order ships with a protocol guide for laboratory research reference.